期刊文献+

抗凝药物发展的历史及最新进展 被引量:3

Anticoagulants: a review of its history and newly use
原文传递
导出
摘要 抗凝药物是通过影响凝血过程中的某些凝血因子阻止凝血过程的药物,可用于防止血管内栓塞或血栓形成的疾病,预防中风或其他血栓性疾病。对于血管外科医师来说,在新药层出不穷的今天,回顾抗凝药的发展历程、分类、抗凝机制以及了解其最新进展,无疑是十分重要的。本文就抗凝药的历史及应用进展作一综述。 Anticoagulants is the drugs which prevent blood clotting process by affecting coagulation factor. They can be used for prevention of thromboembolic disease and stroke. As we stand on the threshold of a new era of anticoagulants, it is time to take an overview of the different types of anticoagulants and how to use them in the management of some specific conditions, including pregnancy, renal impairment, heparin- induced thrombocytopenia and cancer.
出处 《国际外科学杂志》 2011年第12期828-832,共5页 International Journal of Surgery
关键词 抗凝药 发展 临床应用 Anticoagulants Development Clinical use
  • 相关文献

参考文献25

  • 1Fye WB. Heparin : the contribution of William Henry Howell [ J ]. Circulation, 1984, 69(6) : 1198-1203.
  • 2Lauver DA, Booth EA, White A J, et al. Sulodexide arLenuates myocardial ischemia/reperfasion injury and the depositiou of C-reactive protein in areas of infarction without affecting hemostasis[ J]. J Pharmacol Exp Ther, 2005, 312(2) : 794-800.
  • 3Achour A, Kacem M, Dibej K, et al. One year course of oral sulo- dexide in the management of diabetic nephropathy [ J ]. J Neophrol, 2005, 18(5) : 568-574.
  • 4Magnani HN, Gallus A. Heparin-induced thrombocytopenia (HIT). A report of 1 478 clinical outcomes of patients treated with danapariod ( orgaran ) from 1982 to mid-2004 [ J ]. Thromb Haemost, 2006, 95(6) : 967-981.
  • 5Schofield FW. Damaged sweet clover: the cause of a new disease in cattle simulating hemorrhagic septicemia and blackleg[J]. J Am Vet Med Assoc, 1924, 64: 553-575.
  • 6Link KP. The discovery of dicumarol and its sequels[J]. Circulation, 1959, 19(1) : 97-107.
  • 7Holmes RW, Love J. Suicide attempt with warfarin, a bishydroxy- coumarin- like rodenticide [ J ]. J Am Med Assoc, 1952, 148 ( 11 ) : 935-937.
  • 8Haycraft JB. Uber die einwirkung blutegels auf die gerinnbarkeit des Pharmakil, 1884, 18: 209.
  • 9eines sekretes des officinellen blutes [ J ]. Arch Exp Pathol Markwardt F. Isolation and chemical characterization of hirudins [ J ]. Hoppe Seylersz Physiol Chem, 1957,308 (2/4) : 147-156.
  • 10Fortkamp E, Rieger M, Heisterberg-Moutses G, et al. Cloning and expression in escherichia coli of a synthetic DNA for hirudin, the blood coagulation inhibitor in the leech[ J]. DNA, 1986, 5 (6) : 511-517.

同被引文献30

  • 1郁正亚.围手术期抗凝药物的使用[J].中华临床医师杂志(电子版),2011,5(16):4778-4783. 被引量:12
  • 2Baudo F, de Cataldo F, Mostarda G, et al. Management of patients on long-time oral anticoagulant therapy undergoing elective surgery: survey of the clinical practice in the Italian anticoagulant clinics [J]. Intern Emerg Med, 2007, 2(4) : 280-284.
  • 3Siegal D, Yudin J, Kaatz S, et al. Periprocedural heparin bridging in patients receiving K antagonists: systematic review and meta-a- nalysis of bleeding and thromboembnlic rates [ J]. Circulation, 2012, 126(13): 1630-1639.
  • 4Spyropoulos AC, Turpie AG, Dunn AS, et al. Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry [ J ]. J Thromb Haemost, 2006, 4 ( 6 ) : 1246-1252.
  • 5Guyatt GH, Norris SL, Schulman S, et al. Methodology for the de- velopment of antithrombotic therapy and prevention of thrombosis guidelines: antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines[J]. Chest, 2012, 141 (2 Suppl) : 53S-70S.
  • 6Halbritter KM, Wawer A, Beyer J, et al. Bridging anticoagulation for patients on long-term vitamin-K-antagonists: a prospective 1 year registry of 311 episodes [ J]. J Thromb Haemost, 2005, 3 (12) : 2823-2825.
  • 7Spyropoulos AC, Douketis JD, Gorotziafas G, et al. Periprocedural an- tithrombotic and bridging therapy: recommendation for standm'dized re- porting in patients with arterial indications for chronic oral anticoagulant therapy[J]. J Thromb Haemost, 2012, 10(4) : 692-694.
  • 8Matsuoka T, Inoue K, Mizuno K, et al. Herprin as bridging antico- agulant and antiplatelet therapy during the perioperative period[ J]. Hinyokika Kiyo, 2012, 58(5): 223-226.
  • 9Ganter MT, Hofer CK. Principles of perioperative coagulant man- agement[J]. Unfallchirurg, 2012, 115(4): 353-362.
  • 10O' Donnell M, Oczkowski W, Fang J, et al. Preadmission an- tithrombotic treatment and stroke severity in patients with atrial fi- brillation and acute ischaemic stroke : an observational study [ J ]. Lancet Neurol, 2006, 5 (9): 749-754.

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部